Skip to main content

Table 4 Histone deacetylase inhibitors in clinical trials

From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Study Agents

Other agents

Disease

Dosage

Clinical trails

No Pts

Response

Reference

Vorinostat

Idarubicin, Cytarabine

untreated AML

500 mg po tid d1-3

Phase II

52

CR/CRp: 80%

[37]

Vorinostat

decitabine

untreated, relapsed AML

400 mg qd, po 1-7d or 1-14d

Phase I/II

72

MTD not reached

[38]

  1. Abbreviations: CR: complete remission; CRp: CR without platelet recovery; MTD: maximal tolerated dose;